Performance of a novel keratinocyte-based reporter cell line to screen skin sensitizers in vitro.
Emter
Roger
R
Givaudan Schweiz AG, Ueberlandstrasse 138, CH-8600 Duebendorf, Switzerland.
Ellis
Graham
G
Natsch
Andreas
A
D000826:Animal Testing Alternatives; D000975:Antioxidants / Q000378:metabolism*; D001665:Binding Sites; D002460:Cell Line; D002470:Cell Survival; D003877:Dermatitis, Contact / Q000209:etiology*; D004305:Dose-Response Relationship, Drug; D005786:Gene Expression Regulation / Q000187:drug effects; D017930:Genes, Reporter; D057166:High-Throughput Screening Assays; D006801:Humans; D006913:Hydroxysteroid Dehydrogenases / Q000235:genetics*; D020128:Inhibitory Concentration 50; D015603:Keratinocytes / Q000187:drug effects* / Q000201:enzymology; D008156:Luciferases / Q000096:biosynthesis* / Q000235:genetics; D015203:Reproducibility of Results; D020218:Response Elements / Q000187:drug effects; D018570:Risk Assessment; D012882:Skin Tests / Q000379:methods*; D014162:Transfection; D045002:3-alpha-Hydroxysteroid Dehydrogenase (B-Specific)
D000975:Antioxidants; D006913:Hydroxysteroid Dehydrogenases; D008156:Luciferases; C435496:AKR1C2 protein, human; D045002:3-alpha-Hydroxysteroid Dehydrogenase (B-Specific)